Mayne Pharma Group Limited (ASX:MYX)
Australia · Delayed Price · Currency is AUD 3.270
+0.010 (0.31%)
Aug 12, 2026, 4:11 PM AEST
Mayne Pharma Group Financials Overview
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue Revenue Growth | 407.11 | 408.1 | 388.4 | 183.59 | 157.15 | 400.78 |
Revenue Growth | -0.24% | 5.07% | 111.56% | 16.82% | -60.79% | -12.30% |
Gross Profit Gross Profit Growth | 254.99 | 247.27 | 218.78 | 83.49 | 71.57 | 181.98 |
Operating Income Operating Income Growth | -38.19 | -22.03 | -77.84 | -183.43 | -122.53 | -12.4 |
Net Income Net Income Growth | -83.23 | -93.84 | -174.23 | 117.25 | -281.29 | -208.42 |
Earnings Per Share EPS Growth | -1.05 | -1.19 | -2.19 | 1.43 | -3.42 | -2.65 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Women's Health Women's Health Growth | 180.61 | 178.37 | 142.83 | 61.89 | 10.57 | 7.53 |
Dermatology Dermatology Growth | 151.32 | 154.09 | 174.86 | 56.99 | 92.21 | 268.41 |
International International Growth | 75.18 | 75.64 | 70.71 | 64.7 | 54.37 | 42.76 |
Total Total Growth | 407.11 | 408.1 | 388.4 | 183.59 | 157.15 | 400.78 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Investments Cash & Investments Growth | 67.45 | 100.4 | 149.28 | 220.14 | 98.01 | 97.98 |
Total Debt Total Debt Growth | 42.47 | 41.27 | 38.82 | 47.51 | 413.67 | 347.9 |
Net Cash (Debt) Net Cash Growth | 24.98 | 59.13 | 110.46 | 172.64 | -315.66 | -249.92 |
Net Cash Growth | -57.75% | -46.47% | -36.02% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.31 | 0.75 | 1.39 | 2.10 | -3.84 | -3.18 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 21.65 | 17.47 | -15.3 | -42.71 | -7.21 | 58.86 |
Capital Expenditures CapEx Growth | -6.71 | -12.28 | -7.95 | -8.34 | -10.01 | -17.09 |
Free Cash Flow Free Cash Flow Growth | 14.94 | 5.19 | -23.25 | -51.05 | -17.22 | 41.77 |
Free Cash Flow Growth | 187.60% | - | - | - | - | -59.68% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Gross Margin | 62.63% | 60.59% | 56.33% | 45.48% | 45.54% | 45.41% |
Operating Margin | -9.38% | -5.40% | -20.04% | -99.92% | -77.97% | -3.09% |
Pretax Margin | -15.48% | -20.41% | -48.94% | -146.91% | -92.64% | -65.84% |
Profit Margin | -20.44% | -22.99% | -44.86% | 63.87% | -179.00% | -52.00% |
FCF Margin | 3.67% | 1.27% | -5.99% | -27.81% | -10.96% | 10.42% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | - | - | 3.13 | - | - |
Forward PE | - | 150.33 | 150.33 | 150.33 | 150.33 | 150.33 |
P/FCF Ratio | 17.73 | 78.23 | - | - | - | 13.52 |
PS Ratio | 0.65 | 1.00 | 0.99 | 2.00 | 2.81 | 1.41 |